ScreenerHero

ALMSAlumis Inc. Common Stock

NAS · US · Healthcare · Biotechnology · alumis.com
24.17USD+0.75%Mkt Cap: 3.13B $P/E: —

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.13B $
Enterprise Value2.49B $
Revenue (TTM)7.40M $
Gross Profit7.40M $
Net Income (TTM)-243.32M $
Revenue/Share0.0640 USD
Last Price24.17 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees237
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.97
PEG—
EV/EBITDA-5.92
EV/Revenue336.99
P/S399.96
P/B6.50
EPS (TTM)-3.91
EPS (Forward)-2.87
52W Range
3.76076% of range30.77
52W High30.77 USD
52W Low3.760 USD
Profitability
Gross Margin100.00%
Oper. Margin-6439.89%
EBITDA Margin0.00%
Profit Margin-1011.75%
ROE-80.76%
ROA-59.07%
Growth
Revenue Growth-37.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-369.52M $
CapEx (TTM)653.00K $
FCF Margin-2820.19%
FCF Yield-6.67%
Net Debt-465.87M $
Net Debt/EBITDA1.11
Balance Sheet
Debt/Equity0.12
Current Ratio6.74
Quick Ratio6.64
Book Value/Sh3.519 USD
Cash/Share3.881 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)40.33 USD
Upside (mean)+66.9%
Target Range25.00 USD – 55.00 USD
$25.00+66.9% to mean$55.00
# Analysts9
Ownership
Shares Out.129.44M
Float98.56M
Insiders0.52%
Institutions93.64%
Short Interest
Short Ratio4.2d
Short % Float8.05%
Short % Out.4.52%
Shares Short5.77M
Short (prev mo.)14.29M
Technical
SMA 5026.35 (-8.3%)
SMA 20021.45 (+12.7%)
Beta-0.67
S&P 52W Chg18.16%
Avg Vol (30d)976.43K
Avg Vol (10d)906.03K
Technical Indicators
RSI (14)40.7
MACD-0.5980
MACD Signal-0.1739
MACD Hist.-0.4241
BB Upper29.50 USD
BB Middle26.58 USD
BB Lower23.65 USD
BB Width22.01%
ATR (14)1.829 USD
Vol Ratio (20d)1.03x